Rhythm Pharmaceuticals, Inc. (RYTM)
Healthcare • Biotechnology
StockNasdaqGMUnited StatesUS76243J1051
109.86 USD
-2.05% today Updated 13 Nov 2026 10:46
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Rhythm Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 10:46. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
25 Feb 2027
in 104 days · 08:00 · estimate -3.20
Last results
-0.61 vs -0.71 estimated
03 Nov 2026 · Beat +13.9%
Beat the estimate
8 of 12
3 missed · 1 in line · 4 beats in a row
Average surprise
+3.1%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | -3.20 | — | — | Upcoming |
| 03 Nov 2026 08:00 | -0.71 | -0.61 | +13.9% | Beat |
| 04 Aug 2026 07:00 | -0.83 | -0.73 | +12.4% | Beat |
| 05 May 2026 07:00 | -0.86 | -0.83 | +3.6% | Beat |
| 26 Feb 2026 07:00 | -0.78 | -0.73 | +6.4% | Beat |
| 04 Nov 2025 07:00 | -0.73 | -0.82 | -11.7% | Miss |
| 05 Aug 2025 07:00 | -0.67 | -0.75 | -12.1% | Miss |
| 07 May 2025 07:00 | -0.68 | -0.81 | -19.4% | Miss |
| 26 Feb 2025 07:00 | -0.73 | -0.72 | +1.4% | Beat |
| 05 Nov 2024 16:00 | -0.87 | -0.73 | +16.0% | Beat |
| 06 Aug 2024 07:00 | -0.72 | -0.55 | +23.8% | Beat |
| 07 May 2024 07:00 | -2.39 | -2.35 | +1.7% | Beat |
| 22 Feb 2024 07:00 | -0.71 | -0.70 | +0.9% | In line |
| 07 Nov 2023 07:00 | -0.76 | -0.76 | -0.4% | In line |
| 01 Aug 2023 07:00 | -0.78 | -0.82 | -4.7% | Miss |
| 02 May 2023 07:00 | -0.77 | -0.92 | -19.1% | Miss |
| 01 Mar 2023 17:00 | -0.78 | -0.74 | +5.1% | Beat |
| 08 Nov 2022 07:00 | -0.98 | -0.79 | +19.1% | Beat |
| 02 Aug 2022 07:00 | -1.03 | -0.89 | +13.4% | Beat |
| 03 May 2022 07:00 | -1.04 | -1.05 | -0.8% | In line |
| 01 Mar 2022 07:00 | -0.93 | -0.85 | +8.6% | Beat |
| 02 Nov 2021 07:00 | -0.83 | -0.70 | +15.7% | Beat |
| 03 Aug 2021 15:00 | -0.74 | -0.70 | +5.4% | Beat |
| 03 May 2021 08:00 | -0.69 | -0.47 | +32.4% | Beat |
| 01 Mar 2021 09:00 | -0.79 | -0.79 | 0.0% | In line |
| 02 Nov 2020 11:00 | -0.80 | -0.77 | +3.8% | Beat |
| 03 Aug 2020 09:00 | -0.82 | -0.71 | +13.4% | Beat |
| 04 May 2020 08:00 | -0.82 | -0.78 | +4.6% | Beat |
| 02 Mar 2020 08:00 | -0.92 | -0.78 | +15.0% | Beat |
| 01 Nov 2019 08:00 | -1.10 | -1.04 | +5.2% | Beat |
| 29 Jul 2019 16:00 | -0.85 | -1.24 | -45.3% | Miss |
| 03 May 2019 08:00 | -0.73 | -0.84 | -15.6% | Miss |
| 08 Mar 2019 08:00 | -0.66 | -0.74 | -12.1% | Miss |
| 09 Nov 2018 08:00 | -0.61 | -0.52 | +14.8% | Beat |
| 08 Aug 2018 16:00 | -0.47 | -0.52 | -10.6% | Miss |
| 14 May 2018 08:00 | -0.42 | -0.60 | -42.9% | Miss |
| 12 Mar 2018 16:00 | -0.55 | -0.41 | +25.5% | Beat |
| 14 Nov 2017 07:00 | -0.56 | -0.66 | -18.9% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 189.8M | +45.8% | -196.5M | -103.6% | -3.11 | +28.3% | -116.6M |
| 2024 | 130.1M | +68.1% | -260.6M | -200.3% | -4.34 | -35.6% | -113.9M |
| 2023 | 77.4M | +227.6% | -184.7M | -238.5% | -3.20 | +7.8% | -136.2M |
| 2022 | 23.6M | — | -181.1M | -766.2% | -3.47 | — | -177.7M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 112.26 | 112.26 | 108.88 | 109.86 | -2.05% | 1,064,800 | |
| 11 Nov 2026 | 113.76 | 115.20 | 112.04 | 112.16 | -1.57% | 740,300 | |
| 10 Nov 2026 | 113.42 | 115.06 | 112.50 | 113.95 | +0.01% | 616,000 | |
| 09 Nov 2026 | 112.31 | 114.98 | 110.75 | 113.94 | +1.48% | 1,287,200 | |
| 06 Nov 2026 | 107.10 | 113.29 | 104.31 | 112.28 | +6.91% | 4,935,400 | |
| 05 Nov 2026 | 108.76 | 110.66 | 103.06 | 105.02 | -5.11% | 6,395,800 | |
| 04 Nov 2026 | 85.94 | 110.68 | 85.04 | 110.68 | +28.04% | 5,485,800 | |
| 03 Nov 2026 | 84.83 | 89.28 | 81.57 | 86.44 | -7.49% | 7,109,800 | |
| 02 Nov 2026 | 93.13 | 95.35 | 92.40 | 93.44 | +0.94% | 2,003,900 | |
| 30 Oct 2026 | 93.48 | 95.60 | 91.42 | 92.57 | -0.54% | 431,700 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot (opens in a new tab) SeekingAlpha · 10 Nov 2026 09:56
- Guggenheim Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $147 (opens in a new tab) Benzinga · 05 Nov 2026 12:12
- Rhythm Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 05 Nov 2026 05:24
- AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say (opens in a new tab) Reuters · 04 Nov 2026 22:21
- AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals (opens in a new tab) The Wall Street Journal · 04 Nov 2026 22:21
- RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report (opens in a new tab) Stocktwits · 04 Nov 2026 22:20
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report (opens in a new tab) Investing.com · 04 Nov 2026 21:53
- Could Rhythm Pharmaceuticals (RYTM) Be Too Pricey After Recent Funding? (opens in a new tab) Simply Wall St. · 04 Nov 2026 18:16
- 'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive (opens in a new tab) Benzinga · 04 Nov 2026 16:59
- Rhythm Pharmaceuticals Stock In Focus After Earnings Beat And $750 Million Financing (opens in a new tab) Simply Wall St. · 04 Nov 2026 14:16
- Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome (opens in a new tab) 04 Nov 2026 13:00
- What Does Rhythm Pharmaceuticals (RYTM) Mean With A $750 Million Financing Deal? (opens in a new tab) Simply Wall St. · 04 Nov 2026 10:20
- Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166 (opens in a new tab) Benzinga · 04 Nov 2026 09:53
- Rhythm Pharmaceuticals Receives Positive Guidance For IMCIVREE From National Institute For Health And Care Excellence To Add Adults With Bardet-Biedl Syndrome (opens in a new tab) Benzinga · 04 Nov 2026 09:03
- Rhythm Pharmaceuticals (RYTM) Dropped, So What Is Behind The Fresh Attention? (opens in a new tab) Simply Wall St. · 04 Nov 2026 07:10
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 112.16 USD
- Market cap
- 7.6B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow RYTM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.